NeuroSense Therapeutics Ltd. (NRSN) NASDAQ
0.80
-0.0166(-2.04%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
0.80
-0.0166(-2.04%)
Currency In USD
Sector
Healthcare
Industry
Biotechnology
Employees
17
First IPO Date
December 09, 2021
| Name | Title | Pay | Year Born |
| Alon Ben-Noon | Co-Founder, Chief Executive Officer & Director | 392,000 | 1979 |
| Niva Russek-Blum | Chief Technology Officer | 201,000 | 1979 |
| Or Eisenberg | Chief Financial Officer | 273,000 | 1981 |
| Ferenc Tracik | Chief Medical Officer | 447,000 | 1964 |
| Keren Pushett | Head of HR | 0 | N/A |
| Yael Barak | Vice President of Quality & Compliance | 0 | 1970 |
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.